{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:24:28Z","timestamp":1786987468635,"version":"build-2736575974"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.critrevonc.2018.11.009","type":"journal-article","created":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T17:25:07Z","timestamp":1543685107000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-6344","authenticated-orcid":false,"given":"Liliana","family":"Belgioia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Errico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Daidone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-7908","authenticated-orcid":false,"given":"Paolo","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Greto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.009_bib0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2014.04.006","article-title":"A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer","volume":"67","author":"Albiges","year":"2015","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.009_bib0010","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3171\/2015.4.JNS142200","article-title":"Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival","volume":"124","author":"Babu","year":"2016","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0015","series-title":"Comprehensive Geriatric Oncology","first-page":"463","author":"Balducci","year":"2004"},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2016.05.014","article-title":"Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer","volume":"98","author":"Boyer","year":"2016","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.009_bib0030","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.7314\/APJCP.2013.14.10.5699","article-title":"Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure","volume":"14","author":"Cai","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0035","unstructured":"Cancer Research UK, http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence\/age#heading-Zero, Accessed December 2017."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0040","unstructured":"Cancer Research UK, http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence#heading-Two, Accessed December 2017."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.009_bib0045","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2217\/fon-2017-0457","article-title":"Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial","volume":"14","author":"Chen","year":"2018","journal-title":"Fut. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0050","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/0008-5472.CAN-04-3547","article-title":"Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib","volume":"65","author":"Chinnaiyan","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejca.2016.10.005","article-title":"Targeted therapy and elderly people: a review","volume":"69","author":"Daste","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2017.05.044","article-title":"Immune checkpoint inhibitors and elderly people: a review","volume":"82","author":"Daste","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"33","key":"10.1016\/j.critrevonc.2018.11.009_bib0065","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1200\/JCO.2006.07.0268","article-title":"Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712","volume":"24","author":"Davies","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0070","article-title":"Trastuzumab and hypofractionated whole breast radiotherapy: a victorious combination?","author":"De Santis","year":"2017","journal-title":"Clin. Breast Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.009_bib0075","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.009_bib0080","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00405-016-4336-3","article-title":"Radiotherapy for elderly patients and cetuximab, a monocentric study","volume":"274","author":"Falk","year":"2017","journal-title":"Eur. Arch. Otorhinolaryngol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.009_bib0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.breast.2013.11.011","article-title":"Treatment of HER2-positive breast cancer","volume":"23","author":"Figueroa-Magalh\u00e3es","year":"2014","journal-title":"Breast"},{"issue":"March (2)","key":"10.1016\/j.critrevonc.2018.11.009_bib0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000488252","article-title":"Radiotherapy and vascular endothelial growth factor receptor-tyrosine kinase inhibitors in renal Cancer","volume":"63","author":"Fiore","year":"2018","journal-title":"Chemotherapy"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.009_bib0095","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/j.jaad.2013.11.032","article-title":"Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin","volume":"70","author":"Gathings","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","article-title":"High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes","volume":"90","author":"Giro","year":"2009","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.009_bib0105","first-page":"264","article-title":"The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers","volume":"4","author":"Glynne-Jones","year":"2013","journal-title":"J. Gastrointest. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.009_bib0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.radonc.2017.11.004","article-title":"The population benefit of evidence-based radiotherapy: 5-Year local control and overall survival benefits","volume":"126","author":"Hanna","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0115","series-title":"International Population Reports Issued March","author":"He","year":"2015"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.009_bib0120","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","article-title":"A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma","volume":"96","author":"Hiniker","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"34","key":"10.1016\/j.critrevonc.2018.11.009_bib0125","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","article-title":"Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer","volume":"32","author":"Iyengar","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000351617","article-title":"Erlotinib and radiation therapy for elderly patients withesophageal cancer- clinical and correlative results from a prospective multicenter phase 2 trial","volume":"85","author":"Iyer","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1758-3284-2-34","article-title":"Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience","volume":"2","author":"Jensen","year":"2010","journal-title":"Head Neck Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.009_bib0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11523-013-0280-y","article-title":"Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases","volume":"9","author":"Kao","year":"2014","journal-title":"Target. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0145","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","article-title":"Phase III Trial of maintenance gefitinib or placebo after concurrent chemotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023","volume":"26","author":"Kelly","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.009_bib0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2011.05.016","article-title":"Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial","volume":"48","author":"Kennecke","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.009_bib0155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3340\/jkns.2015.58.3.205","article-title":"Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for brain metastases originating from non-small-cell lung cancer","volume":"58","author":"Kim","year":"2015","journal-title":"J. Korean Neurosurg. Soc."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.009_bib0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","article-title":"Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone","volume":"18","author":"Koller","year":"2017","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.009_bib0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2015.02.005","article-title":"Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small-cell lung cancer","volume":"92","author":"Komaki","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2018.11.009_bib0170","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1442-2042.2010.02706.x","article-title":"Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature","volume":"18","author":"Kusuda","year":"2011","journal-title":"Int. J. Urol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.11.009_bib0175","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.009_bib0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","article-title":"Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme","volume":"29","author":"Lai","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.009_bib0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2013.08.012","article-title":"Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer","volume":"109","author":"Lartigau","year":"2013","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0190","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.1998.16.9.3078","article-title":"Southwet Oncology Group phase II trial of concurrent carboplatin, etoposide and radiation for poor-risk stage III non small-cell lung cancer","volume":"16","author":"Lau","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.009_bib0195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/JTO.0000000000000347","article-title":"A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)\/RTOG 0972 (NRG)","volume":"10","author":"Lilenbaum","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.009_bib0200","doi-asserted-by":"crossref","first-page":"e5747","DOI":"10.1097\/MD.0000000000005747","article-title":"Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: three case reports","volume":"96","author":"Lu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0205","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial","volume":"34","author":"Magrini","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.009_bib0210","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CJI.0000000000000198","article-title":"Pneumonitis in irradiated lungs after nivolumab: a brief communication and review of the literature","volume":"41","author":"Manapov","year":"2018","journal-title":"J. Immunother."},{"issue":"February (1)","key":"10.1016\/j.critrevonc.2018.11.009_bib0215","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12885-018-4117-z","article-title":"Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data","volume":"18","author":"Maroun","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0220","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/OTT.S89755","article-title":"Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer a phase II trial","volume":"9","author":"Martinez","year":"2016","journal-title":"Onco Targets Therapy"},{"issue":"11","key":"10.1016\/j.critrevonc.2018.11.009_bib0225","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2012.46.3299","article-title":"Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial","volume":"31","author":"Martins","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"April (5)","key":"10.1016\/j.critrevonc.2018.11.009_bib0230","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2016.12.018","article-title":"A phase 1\/2 trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation after transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer (Trial NRG oncology RTOG 0524)","volume":"97","author":"Michaelson","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.009_bib0235","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.radonc.2017.07.006","article-title":"Concurrent administration of anti-HER2 therapy and radiotherapy: systematic review","volume":"124","author":"Mignot","year":"2017","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.009_bib0240","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3171\/2016.4.SPINE16229","article-title":"Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma","volume":"25","author":"Miller","year":"2016","journal-title":"J. Neurosurg. Spine"},{"issue":"83","key":"10.1016\/j.critrevonc.2018.11.009_bib0245","article-title":"PD1\/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report","volume":"4","author":"Nagasaka","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"34","key":"10.1016\/j.critrevonc.2018.11.009_bib0250","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","article-title":"Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity","volume":"32","author":"Nguyen-Tan","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2018.11.009_bib0255","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"April","key":"10.1016\/j.critrevonc.2018.11.009_bib0260","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0265","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3892\/mco.2013.135","article-title":"Clinical study on gefitinib combined with \u0263-ray stereotactic body radiation therapy as the first-line treatment regimen for senile patients with adenocarcinoma of the lung (final results of JLY20080085)","volume":"1","author":"Pan","year":"2013","journal-title":"Mol. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.11.009_bib0270","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamadermatol.2015.0326","article-title":"Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma","volume":"151","author":"Pollom","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.11.009_bib0275","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/JTO.0b013e3181eba657","article-title":"Chemoradiotherapy and Gefitinib in stage III non-small cell lung cancer with Epidermal Growth Factor receptor and KRAS mutation analysis. Cancer and Leukemia Group B (CALEB) 30106, a CALGB-stratified phase II trial","volume":"5","author":"Ready","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.009_bib0280","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10238-017-0460-7","article-title":"Are EGFR tyrosine kinase inhibitors effectice in elderly patients with EGFR-mutated non-small cell lung cancer?","volume":"18","author":"Roviello","year":"2018","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0285","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ijrobp.2006.08.076","article-title":"Phase I\/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma","volume":"67","author":"Safran","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.009_bib0290","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/annonc\/mdq736","article-title":"A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers","volume":"22","author":"Salama","year":"2011","journal-title":"Ann. Oncol."},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2018.11.009_bib0295","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/neuonc\/nov300","article-title":"Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy","volume":"18","author":"Saran","year":"2016","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.009_bib0300","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00066-015-0902-7","article-title":"Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck: first clinical experience with vismodegib for locally advanced disease","volume":"192","author":"Schulze","year":"2016","journal-title":"Strahlenther. Onkol."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.009_bib0305","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2007.13.1706","article-title":"Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer","volume":"26","author":"Seiwert","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0310","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.009_bib0315","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdx115","article-title":"Nivolumab induced radiation recall pneumonitis after two years of radiotherapy","volume":"28","author":"Shibaki","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox060","article-title":"Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis","volume":"20","author":"Song","year":"2017","journal-title":"Dis. Esophagus"},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0325","doi-asserted-by":"crossref","first-page":"223","DOI":"10.21037\/tcr.2016.06.29","article-title":"Locoregionally advanced squamous cell carcinoma of the head and neck: chemoradiation or bioradiation","volume":"5","author":"Specenier","year":"2016","journal-title":"Transl. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.009_bib0330","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.2010.09895.x","article-title":"Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma","volume":"108","author":"Staehler","year":"2011","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.009_bib0335","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.urolonc.2010.02.006","article-title":"Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer","volume":"30","author":"Staehler","year":"2012","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0340","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2017.10.006","article-title":"Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy","volume":"313","author":"Stokes","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0345","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/1078-0432.CCR-07-1606","article-title":"Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity","volume":"14","author":"Tanaka","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.009_bib0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cam4.315","article-title":"Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery","volume":"4","author":"Tazi","year":"2015","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.009_bib0355","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1615\/CritRevOncog.2013010591","article-title":"Optimization of immunotherapy in elderly cancer patients","volume":"18","author":"Tomihara","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.009_bib0360","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ijrobp.2014.11.023","article-title":"A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck","volume":"91","author":"Vargo","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0365","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1748-717X-6-105","article-title":"Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study","volume":"6","author":"Velenik","year":"2011","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0370","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"December","key":"10.1016\/j.critrevonc.2018.11.009_bib0375","article-title":"The safety and efficacy of combination therapy of sorafenib and radiotherapy for advanced hepatocellular carcinoma: a retrospective study","author":"Wada","year":"2017","journal-title":"Intern. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2018.11.009_bib0380","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.009_bib0385","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1634\/theoncologist.2010-0030","article-title":"A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I\/II study compared with standard chemoradiation in locally advanced rectal cancer","volume":"15","author":"Willett","year":"2010","journal-title":"Oncologist."},{"issue":"35","key":"10.1016\/j.critrevonc.2018.11.009_bib0390","doi-asserted-by":"crossref","first-page":"38429","DOI":"10.18632\/oncotarget.5193","article-title":"Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: preliminary results of a phase II study","volume":"6","author":"Xu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0395","first-page":"128","article-title":"Cancer in older persons: an international issue in an aging world","volume":"3","author":"Yanvik","year":"2004","journal-title":"Semin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2018.11.009_bib0400","first-page":"E1770","article-title":"Phase II study of Erlotinib and docetaxel with concurrent intensity modulated radiotherapy in locally advanced head and neck squamous cell carcinoma","volume":"38","author":"Yao","year":"2016","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.009_bib0405","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12032-017-0895-4","article-title":"Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence","volume":"34","author":"Yoshida","year":"2017","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.009_bib0410","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1442-2050.2012.01380.x","article-title":"Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study","volume":"26","author":"Zhai","year":"2013","journal-title":"Dis. Esophagus"},{"issue":"23","key":"10.1016\/j.critrevonc.2018.11.009_bib0415","first-page":"1615","article-title":"Phase II study of radiotherapy plus erlotinib for elderly patients with esophageal carcinoma","volume":"92","author":"Zhang","year":"2012","journal-title":"Zhoughua Yi Xue Za Zhi."},{"key":"10.1016\/j.critrevonc.2018.11.009_bib0420","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5807346","article-title":"Combining whole-brain radiotherapy with gefitinib\/erlotinib for brain metastases from non-small-cell lung cancer: a meta-analysis","volume":"2016","author":"Zheng","year":"2016","journal-title":"Biomed Res. Int."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:56:58Z","timestamp":1764863818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818302415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":84,"alternative-id":["S1040842818302415"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.11.009","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}